Bowel perforation from bevacizumab for the management of colorectal cancer

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Bevacizumab (Avastin) is a recently developed monoclonal antibody, which targets the vascular endothelial growth factor receptor pathway, and is currently used in combination with cytotoxic agents as first-line or second-line therapy for patients with metastatic colon cancer. Common complications from administration of bevacizumab include hypertension, proteinuria, and diarrhea. These complications are typically managed conservatively. More serious complications of bevacizumab administration include venous thromboembolism, bleeding, and bowel perforation. Although these complications are much more infrequent, prompt recognition is imperative for adequate and timely management. In this report, we discuss a patient with bowel perforation from bevacizumab for the treatment of metastatic colorectal cancer.

Original languageEnglish (US)
Pages (from-to)S19-S21
JournalAnti-Cancer Drugs
Issue numberSPEC. ISS. 2
StatePublished - May 2009


  • Acute abdomen
  • Adjuvant chemotherapy

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research


Dive into the research topics of 'Bowel perforation from bevacizumab for the management of colorectal cancer'. Together they form a unique fingerprint.

Cite this